Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label gantenerumab rollover study in Alzheimer's disease
NL-OMON52334Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of gantenerumab in Alzheimer's disease (AD) (2 arms), sponsored by Roche. Primary endpoints: Adverse events and serious adverse events, Safety assessments and 4 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON52334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52334.